Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660825 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2L3MBTL1MAPTMAOB | |
| SCHEMBL25229236 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2L3MBTL1MAPTBCHE | |
| SCHEMBL25660826 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2L3MBTL1MAPTBCHE | |
| SCHEMBL23754728 | 0.85 | LMNA (0.59) | LMNASMN1; SMN2L3MBTL1MAPTBCHE | |
| SCHEMBL4843195 | 0.85 | L3MBTL1 (0.61) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL30427250 | 0.85 | LMNA (0.54) | LMNASMN1; SMN2L3MBTL1MAPTBCHE | |
| SCHEMBL25660823 | 0.85 | LMNA (0.54) | LMNASMN1; SMN2L3MBTL1MAPTBCHE | |
| SCHEMBL25210517 | 0.85 | THRA (0.43) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL5193436 | 0.78 | MAOB (0.45) | MAOB | |
| SCHEMBL5194512 | 0.77 | ALDH1A1 (0.46) | L3MBTL1MAPTMAOBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | UPPTHERA (KR) | 2025-09-02 | — | — | US | disclosed |
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | UPPTHERA (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159515-A1 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | PLK1, BUB1, BUB1B | LMNA 3138/4885SMN1; SMN2 3569/4885L3MBTL1 693/4885 |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | PLK1, BUB1, BUB1B | LMNA 3138/4885SMN1; SMN2 3569/4885L3MBTL1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.